anti-fentanyl monoclonal antibody

Anti-fentanyl monoclonal antibody (specifically referring to the lead candidate CTRX-101, also known as hHY6-F9) is a humanized monoclonal antibody designed to prevent and reverse fentanyl-induced toxicity and overdose. Developed by CounterX Therapeutics in collaboration with the University of Minnesota and the University of Washington, CTRX-101 works by binding and sequestering fentanyl and its analogs in the bloodstream, preventing them from crossing the blood-brain barrier and binding to mu-opioid receptors in the brain. This immunotherapeutic approach effectively blunts the respiratory depression, apnea, and reinforcing effects of fentanyl without precipitating withdrawal or interfering with other medications for opioid use disorder (OUD). CTRX-101 is formulated as a long-acting subcutaneous injection intended for the prevention of accidental overdose in high-risk patients, with IND filing and Phase 1 clinical trials planned for 2026.

Other names

chimeric HY6-F9humanized HY6-F9